Peptifact

Octreotide Side Effects: What the Sandostatin Labels Count, Gallstones First

Octreotide (Sandostatin) side effects from its US labels: biliary abnormalities in 63% of trial patients, heart-rate and conduction changes in acromegaly, gut and glucose effects, thyroid changes, and the warnings each carries.

Robert F · Edited by Caroline S · Published 2026-11-09

Illustration: Polished river stones and an empty glass vial on a cool grey slate surface.
Illustration

Octreotide is a somatostatin analogue. What it is, and what it is used for, is set out in Peptide Lexicon's octreotide entry. This page covers only the side effects in the US labels for the injection and the monthly depot, and it gives the label's own figures where the label has them. For the injection-site reactions that many peptides share, see peptide injection site reactions, and for how side effects compare across the peptide class, see the peptide side effects overview.

Gallbladder and bile

The most frequent reaction in the trials is biliary. The label reports biliary tract abnormalities in 63% of patients: 27% gallstones, 24% sludge without stones and 12% biliary duct dilatation. Stones or sludge were present in 52% of patients treated for 12 months or longer. Fewer than 2% of patients treated for one month or less developed gallstones.

The label also lists cholecystitis, cholangitis and pancreatitis among reactions found after approval, some of which required gallbladder removal.

Heart rate and rhythm

In acromegalic patients the label records sinus bradycardia below 50 beats per minute in 25%, conduction abnormalities in 10% and arrhythmias in 9%. Other ECG changes it names are QT prolongation and axis shifts. The label notes that these changes are not uncommon in acromegaly, and that beta-blockers and other drugs with a slowing effect may need adjustment. One acromegalic patient with severe heart failure worsened on starting treatment and improved when it was stopped, confirmed on rechallenge.

Gut

Diarrhea, loose stools, nausea and abdominal discomfort were each seen in 34% to 61% of acromegalic patients in US studies. 2.6% of those patients discontinued because of these symptoms. In carcinoid tumors and VIPomas the rate was 5% to 10%. The label reports that diarrhea and abdominal discomfort generally resolved more quickly at 300 micrograms a day than at 750 micrograms a day.

Blood sugar and thyroid

Hypoglycemia occurred in 3% and hyperglycemia in 16% of acromegalic patients, and in about 1.5% of other patients. The label recommends glucose monitoring, and says antidiabetic treatment may need adjustment.

In acromegalic patients, biochemical hypothyroidism alone occurred in 12%, goiter in 8%, and 4% needed thyroid replacement. Outside acromegaly the label reports hypothyroidism only in isolated patients and has not reported goiter.

Other reactions

  • Pain on injection: 7.7%
  • Headache: 6%
  • Dizziness: 5%
  • Fatigue, weakness, itching, joint pain, backache, urinary infection, flushing, hair loss and depression: each in 1% to 4% of patients
  • Depressed vitamin B12 levels and abnormal Schilling tests in some patients
  • Steatorrhea and fat malabsorption, which the label links to possible pancreatic exocrine insufficiency
  • Anaphylactoid reactions, including anaphylactic shock, reported in several patients

What is not established

  • Most of the trial figures come from people with acromegaly. Rates in other groups, including people treated for carcinoid tumors, are lower where the label gives them, and this page does not extrapolate.
  • The label states that adverse-reaction rates from one trial cannot be compared directly with another trial's rates.
  • The LAR depot label carries its own adverse-reaction data, which this page does not compare line by line. How the octreotide depot differs from the other monthly somatostatin analogue in approved uses and trial evidence is set out in octreotide vs lanreotide.
  • This page did not open FDA's adverse-event database for octreotide. Any figure from it would need its own dated check.

Who makes the decisions

Decisions about these reactions, including dose, monitoring and whether treatment continues, belong to the prescribing clinician. This page describes the labels and does not replace them.

Sources and dates

  • Sandostatin (octreotide acetate) injection, Novartis, US prescribing information, DailyMed listing, listed 24 July 2026. Sections 5 (warnings and precautions), 6.1 (clinical trials experience) and 6.2 (postmarketing experience) are the basis for every figure above.
  • Sandostatin LAR Depot kit, Novartis, DailyMed listing, listed 23 December 2025. Its label was not compared in this page, so none of its figures appear here.
  • The injection label was read on 9 November 2026.

Frequently asked questions

What are the most common side effects of octreotide?

In acromegaly trials, the most common reactions were gallbladder abnormalities, sinus bradycardia, diarrhea, loose stools and abdominal discomfort. Gallbladder abnormalities were seen in 63% of trial patients, mostly those with acromegaly or psoriasis, and diarrhea, loose stools, nausea and abdominal discomfort in 34% to 61% of acromegalic patients.

Does octreotide cause gallstones?

The label warns that gallbladder abnormalities develop frequently with chronic treatment. Stones or sludge were present in 52% of patients who had been treated for 12 months or longer, against less than 2% of those treated for one month or less who developed gallstones.

Can octreotide slow the heart?

Yes. In acromegalic patients the label records sinus bradycardia below 50 beats per minute in 25%, conduction abnormalities in 10% and arrhythmias in 9%. It notes that beta-blockers and other drugs with a slowing effect may need dose adjustment.

Does octreotide affect blood sugar or the thyroid?

Both are in the label. Hypoglycemia occurred in 3% and hyperglycemia in 16% of acromegalic patients, and the label advises glucose monitoring. Biochemical hypothyroidism occurred in 12% of acromegalic patients and goiter in 8%, and the label recommends periodic thyroid monitoring.

Does octreotide lower vitamin B12?

The label reports depressed vitamin B12 levels and abnormal Schilling tests in some patients, and recommends monitoring B12 during therapy. It gives no percentage for this effect.